Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy.

Journal of acquired immune deficiency syndromes (1999) - 1 Jan 2025

Selzer Lisa, VanderVeen Laurie A, Parvangada Aiyappa, Martin Ross, Collins Sean E, Mehrotra Megha, Callebaut Christian

Abstract excerpt

BACKGROUND: HIV envelope (env) diversity may result in resistance to broadly neutralizing antibodies (bNAbs). Assessment of genotypic or phenotypic susceptibility to antiretroviral treatment is often performed in people with HIV-1 (PWH) and used for clinical trial screening for HIV-1 bNAb susceptibility. Optimal bNAb susceptibility screening methods are not yet clear. METHODS: Phenotypic and genotypic analyses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Drug Resistance, Viral

Share to Genotype

Share to HIV Antibodies

Share to HIV Infections

Source

Identifiers

PMID: 39298557
DOI: 10.1097/QAI.0000000000003528

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy.PMID 39298557Read ↗

Predicting the broadly neutralizing antibody susceptibility of the HIV reservoirSemantic proximity Read ↗

Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.Semantic proximity Read ↗

Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression.Semantic proximity Read ↗

Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresSemantic proximity Read ↗

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune ResponseSemantic proximity Read ↗

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.Semantic proximity Read ↗

Next-generation bNAbs for HIV-1 cure strategiesSemantic proximity Read ↗

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and PreventionSemantic proximity Read ↗

Accurate Prediction for Antibody Resistance of Clinical HIV-1 IsolatesSemantic proximity Read ↗

Accurate Prediction of Antibody Resistance in Clinical HIV-1 IsolatesSemantic proximity Read ↗

Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodiesSemantic proximity Read ↗

Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.